BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the release of study findings. Cybin sponsored the study, which was conducted by Kernel, a leader in noninvasive neuroimaging. Titled “Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS,” the study was published in “Scientific Reports from the Nature Portfolio of Journals” and evaluated the ability of Kernel’s Flow1 system to capture and analyze brain changes resulting from the administration of a psychoactive substance. According to the announcement, the single-blind, placebo-controlled study was the first fNIRS (“fNIRS”) human-neuroimaging study with ketamine ever conducted; the announcement also noted that it was the largest fNIRS study measuring the acute effect of a psychedelic.

The study represents a “significant milestone in the field of neuroimaging,” according to Kernel management, and demonstrated “the remarkable ease and capabilities of Flow1 to explore the physiological effects of psychedelics like ketamine in natural settings.” The company will use the study results to evaluate large-scale clinical study opportunities using its Flow technology. “The feasibility study is truly groundbreaking as it supports Kernel’s ability to measure functional brain activity in real time, using a wearable, convenient device,” said Cybin CEO Doug Drysdale in the press release. “The study results also suggest that a combination of metrics may be predictive of subjective mystical experiences during psychedelic treatment. We are excited about the potential for this technology in expanding our understanding of the mechanisms and effects of psychedelic-based therapeutics on the brain and applications to research and clinical trials, which is essential to Cybin’s goal of developing differentiated therapeutics for people with mental health conditions.”

To view the full press release, visit https://ibn.fm/jxRr4

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork